WallStSmart

Micron Technology Inc (MU)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Pfizer Inc generates 8% more annual revenue ($62.58B vs $58.12B). MU leads profitability with a 41.5% profit margin vs 12.4%. MU appears more attractively valued with a PEG of 0.23. MU earns a higher WallStSmart Score of 83/100 (A-).

MU

Exceptional Buy

83

out of 100

Grade: A-

Growth: 5.3Profit: 10.0Value: 10.0Quality: 8.5
Piotroski: 4/9Altman Z: 3.06

PFE

Hold

49

out of 100

Grade: D+

Growth: 2.0Profit: 6.5Value: 4.7Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MUUndervalued (+61.5%)

Margin of Safety

+61.5%

Fair Value

$992.16

Current Price

$382.09

$610.07 discount

UndervaluedFair: $992.16Overvalued
PFESignificantly Overvalued (-194.9%)

Margin of Safety

-194.9%

Fair Value

$9.25

Current Price

$27.28

$18.03 premium

UndervaluedFair: $9.25Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MU6 strengths · Avg: 10.0/10
Market CapQuality
$446.05B10/10

Mega-cap, among the largest globally

PEG RatioValuation
0.2310/10

Growing faster than its price suggests

Return on EquityProfitability
39.8%10/10

Every $100 of equity generates 40 in profit

Profit MarginProfitability
41.5%10/10

Keeps 42 of every $100 in revenue as profit

Operating MarginProfitability
67.6%10/10

Strong operational efficiency at 67.6%

Altman Z-ScoreHealth
3.0610/10

Safe zone — low bankruptcy risk

PFE4 strengths · Avg: 8.3/10
Market CapQuality
$153.36B9/10

Large-cap with strong market position

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

Operating MarginProfitability
23.9%8/10

Strong operational efficiency at 23.9%

Free Cash FlowQuality
$4.50B8/10

Generating 4.5B in free cash flow

Areas to Watch

MU1 concerns · Avg: 4.0/10
Revenue GrowthGrowth
2.0%4/10

2.0% revenue growth

PFE4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
13.772/10

Expensive relative to growth rate

Revenue GrowthGrowth
-1.2%2/10

Revenue declined 1.2%

EPS GrowthGrowth
-21.3%2/10

Earnings declined 21.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : MU

The strongest argument for MU centers on Market Cap, PEG Ratio, Return on Equity. Profitability is solid with margins at 41.5% and operating margin at 67.6%. PEG of 0.23 suggests the stock is reasonably priced for its growth.

Bull Case : PFE

The strongest argument for PFE centers on Market Cap, Price/Book, Operating Margin.

Bear Case : MU

The primary concerns for MU are Revenue Growth.

Bear Case : PFE

The primary concerns for PFE are Piotroski F-Score, PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

MU profiles as a value stock while PFE is a declining play — different risk/reward profiles.

MU carries more volatility with a beta of 1.54 — expect wider price swings.

MU is growing revenue faster at 2.0% — sustainability is the question.

MU generates stronger free cash flow (6.5B), providing more financial flexibility.

Bottom Line

MU scores higher overall (83/100 vs 49/100), backed by strong 41.5% margins. Both earn "Exceptional Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Micron Technology Inc

TECHNOLOGY · SEMICONDUCTORS · USA

Micron Technology, Inc. is an American producer of computer memory and computer data storage including dynamic random-access memory, flash memory, and USB flash drives. It is headquartered in Boise, Idaho.

Visit Website →

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?